Ionis Pharmaceuticals Inc
(NAS:IONS)
$
35.91
-0.42 (-1.16%)
Market Cap: 5.74 Bil
Enterprise Value: 4.73 Bil
PE Ratio: 0
PB Ratio: 8.65
GF Score: 40/100 Ionis Pharmaceuticals Inc at Guggenheim Genomic Medicines and Rare Disease Day (Virtual) Transcript
Apr 01, 2022 / 05:00PM GMT
Release Date Price:
$38.9
(+5.02%)
Debjit D. Chattopadhyay
Guggenheim Securities, LLC, Research Division - Senior Analyst of Biotechnology
All right. Good afternoon, and thank you for joining Guggenheim's Genomic Medicines and Rare Disease Conference day 2's last half of our session here. I am Debjit. I'm one of the analysts representing the Guggenheim Therapeutics team. It's my privilege to host Ionis Pharmaceuticals' Executive Vice President of Research, Dr. Eric Swayze.
Eric, thank you for your time today.
Eric E. Swayze
Ionis Pharmaceuticals, Inc. - EVP of Research
Well, thank you very much for having us on. Appreciate the opportunity.
Debjit D. Chattopadhyay
Guggenheim Securities, LLC, Research Division - Senior Analyst of Biotechnology
Awesome. So let's just dial straight into it. Ionis' platform obviously has come a long way since mipomersen. You've been here for, you just said like, what, 24 years. You've experienced the whole highs and lows here.
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot